US FDA imposes partial hold on CTI BioPharma’s pacritinib clinical trial
This clinical hold impacts part of the clinical work currently being conducted under the IND and will also affect planned clinical trials. Under the partial clinical hold, clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.